blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3993832

EP3993832 - ANTI-CD38 ANTIBODY AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  08.04.2022
Database last updated on 08.10.2024
FormerThe international publication has been made
Status updated on  15.01.2021
Most recent event   Tooltip25.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Crystal Bioscience Inc.
5980 Horton Street, Suite 405
Emeryville, CA 94608 / US
[2022/19]
Inventor(s)01 / IZQUIERDO, Shelley
c/o Crystal Bioscience Inc.,
3911 Sorrento Valley Boulevard, Suite 110
San Diego, California 92121 / US
02 / COLLARINI, Ellen
c/o Crystal Bioscience Inc.,
3911 Sorrento Valley Boulevard, Suite 110
San Diego, California 92121 / US
03 / IFFLAND, Christel
c/o Crystal Bioscience Inc.,
3911 Sorrento Valley Boulevard, Suite 110
San Diego, California 92121 / US
04 / HARRIMAN, William Don
c/o Crystal Bioscience Inc.,
3911 Sorrento Valley Boulevard, Suite 110
San Diego, California 92121 / US
 [2022/19]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2022/19]
Application number, filing date20835193.226.06.2020
[2022/19]
WO2020US39929
Priority number, dateUS201962870542P03.07.2019         Original published format: US 201962870542 P
[2022/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021003074
Date:07.01.2021
Language:EN
[2021/01]
Type: A1 Application with search report 
No.:EP3993832
Date:11.05.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 07.01.2021 takes the place of the publication of the European patent application.
[2022/19]
Search report(s)International search report - published on:US07.01.2021
(Supplementary) European search report - dispatched on:EP18.09.2023
ClassificationIPC:A61K39/395, C07K16/28
[2022/19]
CPC:
C07K16/2896 (EP,US); A61K39/39558 (US); A61K45/06 (US);
A61K47/60 (US); A61K47/6849 (US); A61P35/00 (US);
C07K2317/21 (EP); C07K2317/24 (EP); C07K2317/33 (EP);
C07K2317/565 (EP,US); C07K2317/622 (EP,US); C07K2317/732 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/19]
TitleGerman:ANTI-CD38-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON[2022/19]
English:ANTI-CD38 ANTIBODY AND METHODS OF USE THEREOF[2022/19]
French:ANTICORPS ANTI-CD38 ET SES PROCÉDÉS D'UTILISATION[2022/19]
Entry into regional phase28.12.2021National basic fee paid 
28.12.2021Search fee paid 
28.12.2021Designation fee(s) paid 
28.12.2021Examination fee paid 
Examination procedure28.12.2021Examination requested  [2022/19]
21.02.2024Amendment by applicant (claims and/or description)
21.02.2024Date on which the examining division has become responsible
Fees paidRenewal fee
13.05.2022Renewal fee patent year 03
31.03.2023Renewal fee patent year 04
25.06.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2012092612  (TAKEDA PHARMACEUTICAL [JP], et al) [I] 1-15 * whole document, especially Examples 1 and 3 paragraphs [0277], [0280] and [0306], Table A, Fig. 1B. *;
 [I]WO2019034753  (TUSK THERAPEUTICS LTD [GB]) [I] 1-15 * whole document, especially paragraphs [166], [176-177], [181] [184-185], Tables 1 and 2 and Figs 5A-B, 9 and 11-13 *;
 [I]WO2019074973  (SANOFI SA [FR], et al) [I] 1-15 * whole document, especially Examples 1, 3 (paragraph [00246]) and 6, Examples 7 and 8 and Example 15, paragraph [00281], Table 1. *;
 [I]  - YU TAO ET AL, "Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity", BMC BIOTECHNOLOGY, vol. 19, no. 1, doi:10.1186/s12896-019-0524-8, (20190522), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530185/pdf/12896_2019_Article_524.pdf, XP055820638 [I] 1-15 * whole document, especially page 2, right column and Figs. 1d, 3a-c and 5c *

DOI:   http://dx.doi.org/10.1186/s12896-019-0524-8
International search[A]WO2017059095  (POTENZA THERAPEUTICS INC [US]) [A] 1-3* entire document *;
 [A]WO2018057669  (ALEXO THERAPEUTICS INC [US]) [A] 1-3 * entire document *;
 [A]US2018265586  (ROSENTHAL ARNON [US], et al) [A] 1-3 * entire document *;
 [A]US2019077877  (TESAR MICHAEL [DE], et al) [A] 1-3 * entire document *;
 [A]WO2019075433  (ADIMAB LLC [US]) [A] 1-3 * entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.